Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar

  |  Issue: July 2021  |  

The study’s limitations included the lack of a control group due to the nature of an observational study, but all patients had previously used the prefilled syringe. Also, the self-reporting of results can lead to recall bias. Additionally, the number of patients in this study was very small, so the results may not be generalizable to the overall RA population.

However, the fear of injection did decrease among these patients who had previously used prefilled syringes, suggesting this new injection pen for YLB113-002 may be preferred by patients.

ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Hibino T, Yoshido T, Sagawa A et al. Qualitative survey-based evaluation of operability and convenience for the etanercept biosimilar YLB113 in a unique injection pen in patients with rheumatoid arthritis. GaBiJournal. 2020; 9(3):100–107.
  2. Merck. News release: Indications expanded for Merck’s etanercept biosimilar Brenzys. 2020 Sep 25.
  3. U.S. Food & Drug Administration. Etanercept (Enbrel) approval letter. 1998 Nov 2.
  4. U.S. Food & Drug Administration. Enbrel (etanercept) label. 1998 Nov 2.
  5. U.S. Food & Drug Administration. Enbrel (etanercept) supplement approval for auto-injector. 2017 Sep 14.

Related Articles

    Rheumatology Drug Updates

    Information on new approvals and medication safety that rheumatologists need to know

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…